- 1. .omega.-Diethylamino-2,6-dimethylacetanilide
- [drug having anesthetic, sedative, analgesic, anticonvulsant and cardiac depressant activities, used as a local anesthetic; applied topically to the skin and mucous membranes. ( CSP )] (UMLS (NCI) C0023660) =Organic Chemical; Pharmacologic Substance =Acetanilides;
local anesthetic;
phenylamide;
[DE700] LOCAL ANESTHETICS, TOPICAL;
[NT300] ANESTHETICS, MUCOSAL;
=2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide Monohydrochloride;
LIDOCAINE MISC. POWDER (GM);
Lidocaine 0.04 MG/MG;
LIDOCAINE 3 %;
LIDOCAINE 5 MG;
LIDOCAINE 1 %;
LIDOCAINE 4 %;
LIDOCAINE 5 %;
LIDOCAINE 10 %;
LIDOCAINE 0.4 %;
LIDOCAINE 2.5 % | - 18. OMIM
- [This database is a catalog of human genes and genetic disorders authored and edited by Dr. Victor A. McKusick and his colleagues at Johns Hopkins and elsewhere, and developed for the World Wide Web by NCBI, the National Center for Biotechnology Information. The database contains textual information and references. It also contains copious links to MEDLINE and sequence records in the Entrez system, and links to additional related resources at NCBI and elsewhere. ( NCI )] (UMLS (NCI) C0950133) Online Mendelian Inheritance in Man =Intellectual Product ;
|
- 2. 3-(o-Methoxyphenoxy)-1,2-propanediol
- [A glyceryl guaiacolate with expectorant effects. Guaifenesin increases respiratory tract mucus secretions, acts as an irritant to gastric vagal receptors and recruits efferent parasympathetic reflexes that cause glandular exocytosis. This agent reduces the viscosity of mucus secretion by reducing adhesiveness and surface tension as well as increasing hydration of mucus. Guaifenesin promotes the efficiency of the mucociliary mechanism important in removing accumulated secretions from the upper and lower airway. ( NCI )] (UMLS (NCI) C0018305) =Organic Chemical; Pharmacologic Substance =Guaiacol;
[RE400] MUCOLYTICS;
[RE302] NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS;
=METHOCARBAMOL;
Guaifenesin 10 MG/ML;
GUAIFENESIN 1200 MG;
Guaifenesin 13.4 MG/ML;
Guaifenesin 17 MG/ML;
GUAIFENESIN 100 MG/5ML;
GUAIFENESIN 250 MG;
GUAIFENESIN 150 MG/5ML;
GUAIFENESIN 200 MG/5ML;
GUAIFENESIN 400 MG;
GUAIFENESIN 25 MG/5ML;
GUAIFENESIN 50 MG;
GUAIFENESIN 250 MG/5ML;
GUAIFENESIN 500 MG;
GUAIFENESIN 600 MG;
GUAIFENESIN 125 MG;
Guaifenesin 15 MG/ML;
GUAIFENESIN 200 MG;
GUAIFENESIN 300 MG;
Guaifenesin 6 MG/ML;
GUAIFENESIN 100 MG;
GUAIFENESIN 800 MG;
GUAIFENESIN 100 MG/15ML;
GUAIFENESIN 575 MG;
Guaifenesin 13.3 MG/ML;
GUAIFENESIN 150 MG;
GUAIFENESIN 75 MG | - 19. OML - Laboratory order
- (UMLS (HL7) C1549257) =Health Care Activity =Event Type;
|
- 3. 6-O-Methylerythromycin
- [semi-synthetic macrolide antibiotic; derivative of erythromycin. ( CSP )] (UMLS (NCI) C0055856) =Organic Chemical; Antibiotic ;
=macrolide antibiotic;
ERYTHROMYCIN;
[AM200] ERYTHROMYCINS/MACROLIDES;
[GA303] H.PYLORI AGENTS =CLARITHROMYCIN 125 MG/5ML;
CLARITHROMYCIN 250 MG;
CLARITHROMYCIN 500 MG;
CLARITHROMYCIN 250 MG/5ML;
CLARITHROMYCIN 187.5 MG/5ML;
CLARITHROMYCIN 28 X 500 MG;
| - 20. OML _ Laboratory order for multiple orders related to a single container of a specimen
- (UMLS (HL7) C1549271) =Health Care Activity =Event Type;
|
- 4. 7-O-[(Methylthio)methyl]paclitaxel
- [An anticancer drug that belongs to the family of drugs called mitotic inhibitors. ( NCI )] (UMLS (NCI) C0796479) beta-(Benzoylamino)-a-hydroxybenzenepropanoic Acid (aR,bS)-(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-Bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-4-[(methylthio)methoxy]-5-oxo-7,11-methano-1H;
beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic Acid (aR,bS)-(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-Bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-4-[(methylthio)methoxy]-5-oxo-7,11-methano-1H;
BMS-184476 =Organic Chemical; Pharmacologic Substance ;
| - 21. OML _ Laboratory order for multiple orders related to a single specimen
- (UMLS (HL7) C1549269) =Health Care Activity =Event Type;
|
- 5. O methylglucose
- [ ] (UMLS (CSP) C0598522) =Carbohydrate ;
| - 22. Ommaya reservoir
- [(o-MY-a REZ-er-vwahr) A device surgically placed under the scalp and used to deliver anticancer drugs to the fluid surrounding the brain and spinal cord. ( NCI )] (UMLS (NCI) C1289878) =Medical Device ;
|
- 6. Omaha System
- [Omaha Visiting Nurse Association, Omaha, NB. ( HL7V3.0 )] (UMLS (HL7) C1615609) =Intellectual Product ;
=Code;
CodeSystem | - 23. ommochrome
- [ ] (UMLS (CSP) C0069485) =Organic Chemical; Biologically Active Substance ;
|
- 7. Omaha Tribe of Nebraska
- (UMLS (HL7) C1554396) =Population Group =NativeEntityContiguous;
| - 24. OMN _ Non-stock requisition order
- (UMLS (HL7) C1549243) =Health Care Activity =Event Type;
|
- 8. Omaha-Ponca
- (UMLS (HL7) C1551963) =Language =Dhegiha;
| - 25. Omohyoid
- (UMLS (NCI) C0224163) =Body Part, Organ, or Organ Component
|
- 9. Omapatrilat
- [A vasopeptidase inhibitor with antihypertensive activity. Omapatrilat exerts its effect by inhibiting angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP). ACE inhibition results in inhibition of the renin-angiotensin-aldosterone system thereby leading to the reduction of vasoconstriction. Inhibition of NEP leads to the inhibition of hydrolyzation of a number of endogenous vasoactive peptides, such as bradykinin and substance P and as NEP is the principal enzyme degrading natriuretic peptides, NEP inhibition also results in an increase in natriuretic peptidase circulation. Ultimately both effects result in blood vessel relaxation. ( NCI )] (UMLS (NCI) C0663645) =Organic Chemical; Pharmacologic Substance ;
| - 26. OMP _ Pharmacy/treatment order
- (UMLS (HL7) C1549245) =Health Care Activity =Event Type;
|
- 10. OMB _ Blood product order
- (UMLS (HL7) C1549263) =Health Care Activity =Event Type;
| - 27. OMPHALITIS OF NEWBORN
- [ ] (UMLS (ICD9CM) C0158947) =Disease or Syndrome ;
|
- 11. OMD _ Diet order
- (UMLS (HL7) C1549239) =Health Care Activity =Event Type;
| - 28. OMS _ Stock requisition order
- (UMLS (HL7) C1549241) =Health Care Activity =Event Type;
|
- 12. omega 6 fatty acid
- [Essential fatty acids obtained from food sources that are necessary for normal biological functions, as well as growth and development. ( NCI )] (UMLS (CSP) C0133860) =Lipid; Biologically Active Substance
| - 29. OMT FOR GEN'L MOBILIZAT
- [ ] (UMLS (ICD9CM) C0178039) =Therapeutic or Preventive Procedure
|
- 13. Omental Fat
- [A fold of peritoneum originating at the stomach and supporting the viscera. ( NCI )] (UMLS (NCI) C0028977) =Body Part, Organ, or Organ Component =Body Part;
| - 30. OMT TO MOVE TISSUE FLUID
- (UMLS (ICD9CM) C0203940) =Therapeutic or Preventive Procedure
|
- 14. OMENTAL REPAIR NEC
- [ ] (UMLS (ICD9CM) C0176981) =Therapeutic or Preventive Procedure
| - 31. OMT WITH HI-VEL,LO-AMPLI
- [ ] (UMLS (ICD9CM) C0178040) =Therapeutic or Preventive Procedure
|
- 15. Omeprazole Magnesium
- (UMLS (NCI) C0771765) =Organic Chemical; Pharmacologic Substance
| - 32. OMT WITH INDIRECT FORCES
- [A manipulative technique where the restrictive barrier is disengaged and the dysfunctional body part is moved away from the restrictive barrier until tissue tension is equal in one or all planes and directions. ( AOT )] (UMLS (ICD9CM) C0203939) =Therapeutic or Preventive Procedure
|
- 16. OMG _ General clinical order
- (UMLS (HL7) C1549255) =Health Care Activity =Event Type;
| - 33. OMT WITH ISOTON,ISOMETRI
- (UMLS (ICD9CM) C0203938) =Therapeutic or Preventive Procedure
|
- 17. OMI _ Imaging order
- (UMLS (HL7) C1549259) =Health Care Activity =Event Type;
| |
home
